Zag Bio Appoints Jan Hillson, M.D., as Chief Medical Officer

Zag Bio, a biotechnology company developing thymus-targeted medicines, appointed Jan Hillson, M.D., as Chief Medical Officer on January 27, 2026.1

Dr. Hillson, a veteran immunologist and rheumatologist with over 20 years of experience in autoimmune and inflammatory diseases, will oversee clinical development and lead the team advancing ZAG-101 for Type 1 diabetes into a first-in-human study in late 2026.1

Previously, Dr. Hillson served as Senior Vice President of Clinical Development at Provention Bio (a Sanofi Company), and held senior roles at Climb Bio, GlycoEra, Alpine Immune Sciences, ChemoCentryx, and Momenta Pharmaceuticals.13

Zag Bio's approach uses bifunctional antibodies to restore immune tolerance in the thymus for treating autoimmune diseases like Type 1 diabetes.1

The company is backed by investors including Polaris Partners, AbbVie Ventures, Sanofi Ventures, and Regeneron Ventures.1

Sources:

1. https://www.businesswire.com/news/home/20260127156445/en/Zag-Bio-Appoints-Jan-Hillson-M.D.-as-Chief-Medical-Officer

3. https://www.news.sanofi.us/2021-11-17-Provention-Bio-Appoints-Jan-Hillson,-M-D-,-as-Senior-Vice-President-of-Clinical-Development